| 초록 |
We engineered human PANC-1-derived extracellular vesicles (EVs) by conjugating the functional ligand RGD onto EV surfaces (rmExo), for pancreatic cancer therapy. rmExo showed enhanced uptake into PACN-1 cells, as compared to bare EVs. To evaluate the chemotherapeutic effect of the drug vehicle, paclitaxel (PTX) loaded into rmExo (rmExo-PTX) was intravenously injected into xenograft mice prepared using PANC-1 cells. The rmExo-PTX-treated group showed a significant reduction in tumor size compared to the free PTX-treated and control groups. The enhanced effect was attributed to the modification of the EVs using RGD, which has high affinity for αvβ3 (a specific RGD receptor) that is highly expressed in pancreatic cancer cells. Moreover, autologous EVs seemed to have more benefits in delivering PTX due to an homing property to parent tumor cells, as exemplified by the reduced effect of RGD-modified PANC-1 EVs on HT29 xenograft mice and RGD-modified U937 EVs on PANC-1 xenograft mice. |
